Chemotherapy News and Research

Latest Chemotherapy News and Research

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.

25 Feb 2010

Lab research targets 'estrogen-receptor positive' breast cancer cells; identifies key protein

In a laboratory study published in the journal Cancer Research, Scott & White Healthcare anatomic pathologist Arundhati Rao, M.D. is a co-investigator looking at the ways in which estrogen can interfere with how chemotherapy does its job in destroying breast cancer cells.

25 Feb 2010

Ovarian transplant: A viable method for fertility treatment

For the first time, a woman has given birth to two children after her fertility was restored using transplants of ovarian tissue that had been removed and frozen during her cancer treatment and then restored once she was cured.

25 Feb 2010

WSU Boonshoft School of Medicine and Miami Valley Hospital form new neuroscience institute

Wright State University Boonshoft School of Medicine and Miami Valley Hospital announced today the formation of the Wright State University & Premier Health Partners Neuroscience Institute to speed the transfer of research discoveries from bench to bedside, improving the diagnosis and treatment of neurological disorders such as stroke. Ohio Governor Ted Strickland and Chancellor of the Ohio Board of Regents Eric Fingerhut joined Wright State University and Miami Valley Hospital officials in making the announcement.

25 Feb 2010

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors.

25 Feb 2010

Philanthropic organizations fund for cancer research studies

Eight philanthropic organizations and families in the Charlotte region have joined forces to create the "Carolinas Kids Cancer Research Coalition," which is providing funding for the introduction of Phase I and Phase II clinical trials by the Pediatric Hematology and Oncology Center at Levine Children's Hospital (LCH).

25 Feb 2010

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.

25 Feb 2010

EpiCept provides business update and fourth-quarter financial highlights

EpiCept Corporation today announced operating and financial results for the fourth quarter and year ended December 31, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

25 Feb 2010

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

Researchers to test Radio-embolisation technique in patients with bowel cancer

Cancer Research UK this week launches a new trial for patients with bowel cancer that has spread to the liver to see whether a new radiotherapy treatment technique is more effective than standard chemotherapy.

24 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

Frozen/thawed ovarian tissue transplant: Woman has two children from separate pregnancies

24 Feb 2010

Over-produced PKC-iota oncogene linked to poor pancreatic cancer patient survival

Researchers at the Mayo Clinic campus in Florida have found that PKC-iota (PKC), an oncogene important in colon and lung cancers, is over-produced in pancreatic cancer and is linked to poor patient survival. They also found that genetically inhibiting PKC in laboratory animals led to a significant decrease in pancreatic tumor growth and spread.

24 Feb 2010

BSD2000 deep hyperthermia combined with chemotherapy improves quality of life in NSCLC patients

BSD Medical Corporation today announced that a study titled “BSD2000 Deep Hyperthermia Combined with Chemotherapy of PT regimen in Patients with Non-small Cell Lung Cancer” has been published in the current issue of The Chinese Journal of Lung Cancer (February 2010;13(2):132–135) by Yang, Zhao, and Wang.

24 Feb 2010

Poniard Pharmaceuticals enters into $20M committed equity financing facility with Commerce Court Small Cap Value Fund

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that it has entered into a committed equity financing facility under which it may sell up to $20 million of its registered common stock to Commerce Court Small Cap Value Fund, Ltd. over an approximately 18-month period. Poniard is not obligated to utilize any of the facility and remains free to enter into other financing transactions.

24 Feb 2010

New Barts Cancer Research UK Centre launched

A new cancer centre, launched today, puts London at the forefront of cancer research.

23 Feb 2010

Catheter insertion technology patent acquired by Acacia Research subsidiary

Acacia Research Corporation announced today that a subsidiary has acquired patents for catheter insertion technology.

23 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

CINJ researchers test malaria drug for colorectal cancer treatment

While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients.

23 Feb 2010

Testosterone replacement therapy may benefit male cancer survivors with testosterone deficiency

A new study has found that many male cancer survivors who develop testosterone deficiency after receiving chemotherapy or radiation therapy have an impaired quality of life and reduced energy levels. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study suggests that young male cancer survivors with testosterone deficiency may benefit from testosterone replacement therapy.

22 Feb 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

Lab research targets 'estrogen-receptor positive' breast cancer cells; identifies key protein

Ovarian transplant: A viable method for fertility treatment

WSU Boonshoft School of Medicine and Miami Valley Hospital form new neuroscience institute

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

Philanthropic organizations fund for cancer research studies

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

EpiCept provides business update and fourth-quarter financial highlights

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Researchers to test Radio-embolisation technique in patients with bowel cancer

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Frozen/thawed ovarian tissue transplant: Woman has two children from separate pregnancies

Over-produced PKC-iota oncogene linked to poor pancreatic cancer patient survival

BSD2000 deep hyperthermia combined with chemotherapy improves quality of life in NSCLC patients

Poniard Pharmaceuticals enters into $20M committed equity financing facility with Commerce Court Small Cap Value Fund

New Barts Cancer Research UK Centre launched

Catheter insertion technology patent acquired by Acacia Research subsidiary

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

CINJ researchers test malaria drug for colorectal cancer treatment

Testosterone replacement therapy may benefit male cancer survivors with testosterone deficiency

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in